Development and testing of a first-in-class series of macrocyclic ATR inhibitors for cancer treatment

被引：0

作者：

Rocca, S. ^{[1
]}

Hansbarger, M. ^{[1
]}

Gill, T. ^{[1
]}

George, E. ^{[2
]}

Rom, I. ^{[1
]}

Weinstein, J. ^{[1
]}

Breslin, H. ^{[3
]}

Jia, L. ^{[3
]}

Simpkins, F. ^{[4
]}

Brown, E. ^{[5
,6
]}

Gilad, O. ^{[7
]}

机构：

[1] Aprea Therapeut Inc, Biol, Doylestown, PA USA

[2] Moffit Canc Ctr, Gynecol Oncol Program, Tampa, FL USA

[3] Aprea Therapeut Inc, Med Chem, Doylestown, PA USA

[4] Univ Penn, Dept Obstet & Gynecol, Perelman Sch Med, Ovarian Canc Res Ctr,Div Gynecol Oncol, Philadelphia, PA 19104 USA

[5] Univ Penn, Perelman Sch Med, Dept Canc Biol, Philadelphia, PA 19104 USA

[6] Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA

[7] Aprea Therapeut Inc, Co Management, Doylestown, PA USA

来源：

EUROPEAN JOURNAL OF CANCER | 2024年 / 211卷

关键词：

D O I：

10.1016/j.ejca.2024.114849

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PB324

引用

页码：S126 / S127

页数：2

共 50 条

[31] Napabucasin: An Update on the First-in-Class Cancer Stemness Inhibitor
Hubbard, Joleen M.
Grothey, Axel
DRUGS, 2017, 77 (10) : 1091 - 1103
[32] Napabucasin: An Update on the First-in-Class Cancer Stemness Inhibitor
Joleen M. Hubbard
Axel Grothey
Drugs, 2017, 77 : 1091 - 1103
[33] DEVELOPMENT OF A FIRST-IN-CLASS HUMANIZED ANTIBODY TARGETING CXCL1 IN BLADDER CANCER
Murakami, Kaoru
Sasaki, Yuka
Furuya, Hideki
Rosser, Charles
JOURNAL OF UROLOGY, 2021, 206 : E729 - E729
[34] FDA approves first-in-class cancer metabolism drug
Mullard, Asher
NATURE REVIEWS DRUG DISCOVERY, 2017, 16 (09) : 593 - 593
[35] Discovery of ixabepilone (IXEMPRA™): A first-in-class epothilone analog for the treatment of metastatic breast cancer
Borzilleri, Robert M.
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2009, 238
[36] Discovery of a first-in-class Aurora A covalent inhibitor for the treatment of triple negative breast cancer
Zhang, Bin
Zhu, Chengchen
Chan, Albert S. C.
Lu, Gui
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2023, 256
[37] IMAB362, a novel first-in-class monoclonal antibody for treatment of pancreatic cancer
Tuereci, Oezlem
Woell, Stefan
Jacobs, Stefan
Mitnacht-Kraus, Rita
Sahin, Ugur
CANCER RESEARCH, 2014, 74 (19)
[38] A first-in-class hemoglobin-floxuridine conjugate for the treatment of advanced stage liver cancer
Brookes, Steve
Cutler, Murray J.
Seo, Jin Seog
Adamson, Gord
Bell, David
CANCER RESEARCH, 2016, 76
[39] First-in-class small molecule inhibitors of ICOS/ICOSL interaction as a novel class of immunomodulators
Abdel-Rahman, Somaya A.
Swiderek, Katarzyna
Gabr, Moustafa T.
RSC MEDICINAL CHEMISTRY, 2023, 14 (09): : 1767 - 1777
[40] Discovery of ATR selective inhibitors for the treatment of cancer
Charrier, Jean-Damien
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 248

← 1 2 3 4 5 →